Article: Oxycodone Naloxone an ADF Option for Chronic Low Back Pain

Oxycodone Naloxone an ADF Option for Chronic Low Back Pain

Fran Lowry

TAMPA, Florida — A novel extended-release formulation of oxycodone and naloxone in a fixed 2:1 ratio (OXN, Purdue Pharma) may be useful as an abuse-deterrent formulation (ADF) option in the treatment of opioid-experienced patients with chronic low back pain.

“Chronic low back pain is a huge public health problem,” Jerry A. Green, MD, from Purdue Pharma, LP, Stamford, Connecticut, told Medscape Medical News. “Many patients receive opioids but still do not obtain pain relief.”

“Naloxone is a potent mu-opioid receptor antagonist and adds to the abuse-deterrent properties of oxycodone,” he said. “We wanted to test OXN, which is currently available in 29 countries outside the [United States], and is under development here, for its ability to relieve moderate to severe pain in patients with chronic low back pain who have been exposed to opioids.”

Dr. Green presented the results from a randomized, double-blind, placebo-controlled trial comparing this formulation with placebo here at the American Pain Society (APS) 33rd Annual Scientific Meeting. The study was funded by Purdue Pharma.

[Read full article here…]

*You must create a free Medscape account to view the article.